LASIK project is underway

Article

A recent LASIK panel symposium has revealed the progresses and plans for the LASIK Quality of Life Collaboration Project.

A recent LASIK panel symposium has revealed the progresses and plans for the LASIK Quality of Life Collaboration Project.

The study, conducted by the US Food and Drug Administration (FDA), National Eye Institute (NEI) and the US Department of Defence (DoD), analyses the patient-reported outcomes of LASIK surgery.

Dr David W. Parke, American Academy of Ophthalmology (AAO) CEO, said: "LASIK has proven to be safe and effective and has high patient satisfaction rates. We expect that a LASIK quality of life study, relying on sound science and relevant clinical experiences, will be able to shed new light on the post-LASIK patient experience."

The FDA, the AAO and the American Society for Cataract and Refractive Surgery (ASCRS) discussed the project's present developments, anticipated developments and the study's phases.

In phase one patient-reported outcomes were assessed with a web-based questionnaire. Phase two will be a clinical study of military personnel called Patient-Reported Outcomes with LASIK (PROWL-1). The subjects will be questioned preoperatively and then at 1, 3 and 6 months postoperatively. The last phase will be named PROWL-2 and will consist of a national multicentre clinical study.

Various studies published suggest that 95% of patients are satisfied with LASIK outcomes. Initial problems with LASIK have been glare, halos and dry-eye.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.